We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by Glenmark Pharmaceuticals Europe Ltd. (R&D).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00859404
First Posted: March 11, 2009
Last Update Posted: September 24, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Glenmark Pharmaceuticals Europe Ltd. (R&D)
  Purpose
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study. One of the four treatment arms is placebo. The duration of treatment is 12 weeks.

Condition Intervention Phase
Asthma Drug: oglemilast Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma

Further study details as provided by Glenmark Pharmaceuticals Europe Ltd. (R&D):

Primary Outcome Measures:
  • Morning pre-dose FEV1 at day 85 compared with pre-dose FEV1 value at day 1 [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Change from baseline at days 8, 36 and 64 in morning pre-dose FEV1 [ Time Frame: Days 8, 36, 64 ]
  • Change from baseline at days 8, 36 and 64 in morning pre-dose vital capacity (FVC), peak expiratory flow (PEF), forced expiratory flow 25-75% (FEF25-75%) [ Time Frame: days 8, 36 and 64 ]
  • Change from baseline in morning and evening PEF (based on patient diary) [ Time Frame: 12 weeks ]
  • Change in asthma day time symptom score from baseline at day 85 [ Time Frame: 12 weeks ]
  • Change in asthma night time symptom score from baseline at day 85 [ Time Frame: 12 weeks ]
  • Change in number of night time awakenings from baseline at day 85 [ Time Frame: 12 weeks ]
  • Frequency and the use of rescue (reliever) medication (salbutamol) [ Time Frame: 12 weeks ]
  • Frequency and severity of asthma exacerbations [ Time Frame: 12 weeks ]
  • Investigator global impression of change from baseline to day 85 [ Time Frame: 12 weeks ]
  • Patient global impression of change from baseline to day 85 [ Time Frame: 12 weeks ]
  • Pharmacokinetic parameters of oglemilast [ Time Frame: 12 weeks ]

Estimated Enrollment: 282
Study Start Date: October 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. oglemilast Drug: oglemilast
Tablet oglemilast or placebo once a day, for 12 weeks
Experimental: 2. oglemilast Drug: oglemilast
Tablet oglemilast or placebo once a day, for 12 weeks
Experimental: 3. oglemilast Drug: oglemilast
Tablet oglemilast or placebo once a day, for 12 weeks
Placebo Comparator: 4. placebo Drug: oglemilast
Tablet oglemilast or placebo once a day, for 12 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria:

  • Adult patients with a physician-documented diagnosis of chronic, stable, persistent, mild to moderate asthma (clinical symptoms and documented reversibility of airway obstruction, with an FEV1 of 60% to 85% of the predicted value).

The following criteria must be met at the randomisation visit:

  • At least 80% compliance during the single-blind placebo run-in period
  • FEV1 between 60% and 85% of the predicted value
  • Without asthma exacerbation during the run-in period
  • Reversibility: patients are required to demonstrate a ≥ 12% increase in FEV1 (with an absolute improvement in FEV1 of at least 200mL) ≥ 10 min and up to 15 minutes after inhalation of 400 μg salbutamol via a spacer
  • Any symptom score being ≥ 1 for at least 4 out of the last 7 days of the run-in
  • Use of salbutamol for symptom relief on > 2 occasions on at least 4 out of the last 7 days of the run-in
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00859404


Locations
India
Glenmark investigational sites (28)
Mumbai, Bangalore etc, India
Sponsors and Collaborators
Glenmark Pharmaceuticals Europe Ltd. (R&D)
  More Information

Responsible Party: Dr Narendra Maharaj, Glenmark Pharmaceuticals Ltd
ClinicalTrials.gov Identifier: NCT00859404     History of Changes
Other Study ID Numbers: GRC 3886-201
First Submitted: March 10, 2009
First Posted: March 11, 2009
Last Update Posted: September 24, 2009
Last Verified: September 2009

Keywords provided by Glenmark Pharmaceuticals Europe Ltd. (R&D):
Mild to moderate persistent asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases